The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, MoonLake Immunotherapeutics (NASDAQ: MLTX) closed at $13.69 down -0.98% from its previous closing price of $13.83. In other words, the price has decreased by -$0.98 from its previous closing price. On the day, 0.94 million shares were traded. MLTX stock price reached its highest trading level at $13.9 during the session, while it also had its lowest trading level at $13.48.
Ratios:
For a deeper understanding of MoonLake Immunotherapeutics’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.50 and its Current Ratio is at 8.50. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.26.
Goldman Downgraded its Buy to Neutral on October 01, 2025, while the target price for the stock was maintained at $7.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 08 ’25 when Santos da Silva Jorge sold 130,000 shares for $15.08 per share. The transaction valued at 1,960,400 led to the insider holds 2,948,577 shares of the business.
Santos da Silva Jorge sold 70,000 shares of MLTX for $1,014,300 on Dec 09 ’25. The Chief Executive Officer now owns 2,878,577 shares after completing the transaction at $14.49 per share. On Dec 08 ’25, another insider, Reich Kristian, who serves as the Chief Scientific Officer of the company, sold 130,000 shares for $15.08 each. As a result, the insider received 1,960,400 and left with 72,908 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLTX now has a Market Capitalization of 970255104 and an Enterprise Value of 569965760.
Stock Price History:
The Beta on a monthly basis for MLTX is 1.20, which has changed by -0.7445983 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, MLTX has reached a high of $62.75, while it has fallen to a 52-week low of $5.95. The 50-Day Moving Average of the stock is 10.62%, while the 200-Day Moving Average is calculated to be -61.23%.
Shares Statistics:
For the past three months, MLTX has traded an average of 5.29M shares per day and 1412640 over the past ten days. A total of 63.70M shares are outstanding, with a floating share count of 63.49M. Insiders hold about 10.39% of the company’s shares, while institutions hold 60.63% stake in the company. Shares short for MLTX as of 1765756800 were 4894840 with a Short Ratio of 0.93, compared to 1763078400 on 3856500. Therefore, it implies a Short% of Shares Outstanding of 4894840 and a Short% of Float of 13.73.
Earnings Estimates
The market rating of MoonLake Immunotherapeutics (MLTX) is currently shaped by the ongoing analysis conducted by 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.89, with high estimates of -$0.68 and low estimates of -$1.01.
Analysts are recommending an EPS of between -$3.46 and -$3.69 for the fiscal current year, implying an average EPS of -$3.58. EPS for the following year is -$3.58, with 10.0 analysts recommending between -$1.83 and -$4.36.
